Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 986-990

  Stack, Anne M ^c   Malley, Richard ^c   Thompson, Claudette M ^c   Kobzik, Les ^c   Siber, George R ^b   Saladino, Richard A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HOST RESISTANCE; INFECTION RESISTANCE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0031981031     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515259     Document Type: Article

References (13)

1. Centers for Disease Control and Prevention. Antibiotic resistance among nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae - Bangui, Central African Republic, 1995. MMWR Morb Mortal Wkly Rep 1997;46(3):62-4.
2. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-24.
3. Zangwill KM, Vadheim CM, Vannier AM, Hememvay LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996;174:752-9.
4. Dagan R, Englehard D, Piccard E. Epidemiology of invasive pneumococcal infections in Israel. JAMA 1992;268:3328-32.
5. Koskela M, Leinonen M, Haiva VM, Timonen M, Makela PH. First and second dose responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986;5:45-50.
6. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165(suppl 1):S49-52.
7. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
8. Kayhty H, Ahman H, Ronnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
9. Vella PP, Marburg S, Staub JM, et al. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex. Infect Immun 1992;60:4977-83.
10. King JC, Vink PE, Parley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:192-6.
11. Leach A, Ceesay SJ, Banya WA, Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996;15:333-9.
12. Santosham M, Reid GR, Almeido-Hill J, Thompson C, Wolff MC, Siber GR. Efficacy of bacterial polysaccharide immune globulin (BPIG) for prevention of bacteremic pneumococcal infections in Apache children [abstract]. Pediatr Res 1992;31:178A.
13. Saladino RA, Stack AM, Fleisher GR, et al. Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats. Infect Immun 1997;65:4701-4.